Abstract: Provided are compounds comprising a first moiety and a second moiety, wherein the first moiety comprises an azabenzene joined to a trivalent nitrogen atom that is part of an at least three-cyclic heteroaromatic ring system. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these compounds.

Abstract: A compound comprising a first ligand LA comprising a structure of Formula I, is provided. In Formula I, moieties A, B, C, and D are each independently a monocyclic ring or a multicyclic fused ring system; each of X1 to X8 is C or N; each independently represents a single bond or a double bond; each of L1, L2, L3, and L4 is independently a direct bond or a linking group; each R, R?, R?, RA, RB, RC, and RD is a hydrogen or a General Substituent; any two adjacent R, R?, R?, RA, RB, RC, and RD may be joined or fused to form a ring; and LA is coordinated to a transition metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound having a ligand LA comprising a structure of Formula I, is provided. In Formula I, moiety A is a monocyclic ring or a polycyclic fused-ring system; each of X1 to X12 is C or N; represents a single bond or a double bond in a Lewis structure; each RA, RB, RC, and RD is hydrogen, metal M, a General Substituent, or a substituent comprising metal M; metal M has an atomic mass of at least 40; and any two substituents may be joined to form a ring. Formulations, OLEDs, and consumer products comprising the compound are also provided.

Abstract: Provided are compounds comprising a 9-membered ring to which four 6-membered carbocyclic or heterocyclic aromatic rings as well as one further 5-membered or 6-membered heterocyclic ring are fused. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) as well as related consumer products that utilize these compounds.

Abstract: Provided are macrocyclic compounds comprising at least one eight-membered ring and at least four further 5-membered or 6-membered carbocyclic and heterocyclic rings which may be further substituted. Also provided are formulations comprising these macrocyclic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these macrocyclic compounds.

Abstract: Provided are organic and organometallic compounds which have a cyclic structure and which comprise at least one of SiR1R2, GeR1R2, P?O, and Se in the cyclic structure. Also provided are formulations comprising these organic and organometallic compounds. Further provided are organic light-emitting devices (OLEDs) and related consumer products that utilize these organic and organometallic compounds.

Abstract: A display device includes a light source, a waveguide element, a liquid crystal coupler, a first holographic optical element and a second holographic optical element. The light source is configured to emit light. The waveguide element is located above the light source. The liquid crystal coupler is located between the waveguide element and the light source. The first holographic optical element is located on a top surface of the waveguide element, in which the liquid crystal coupler is configured to change an incident angle that the light emits to the first holographic optical element. The second holographic optical element is located on the top surface of the waveguide element, and there is a first distance in a horizontal direction between the first holographic optical element and the second holographic optical element, in which the second holographic optical element is configured to diffract the light to the waveguide element below.

Abstract: Provided are organometallic compounds that include a ligand LA of that are useful as emitters in OLEDs. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: A wafer having a first region and a second region is provided. A first topography variation exists between the first region and the second region. A first layer is formed over the first region and over the second region of the wafer. The first layer is patterned. A patterned first layer causes a second topography variation to exist between the first region and the second region. The second topography variation is smoother than the first topography variation. A second layer is formed over the first region and the second region. At least a portion of the second layer is formed over the patterned first layer.

Abstract: A compound of Formula I, is provided. In Formula I, one of Z1, Z2, and Z3 is N and the remainder are C; each of L1 and L2 is independently selected from a direct bond and a linking group; at least one of R1, R2, RA, RB, RC, RD, and RE comprises a group R* having a structure selected form the group consisting of Formula II, -Q(R3)(R4)a(R5)b, Formula III, and Formula IV, Each R, R?, R?, R1, R2, R3, R4, R5, RA, RB, RC, RD, RE, RF, RG, and RH is independently hydrogen or a General Substituent, with the proviso that group R* is not adamantyl. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Provided is a cutting speed planning system including a graphic preprocessing engine, a first speed planning engine, an included angle calculation engine, a second speed planning engine and a speed determination engine. The graphic preprocessing engine substitutes a simplified cutting route for a plurality of short straight paths of a graphic path. The first speed planning engine calculates a reasonable maximum cutting speed of each cutting route. The included angle calculation engine calculates the included angle between two adjacent ones of the cutting routes. The second speed planning engine adjusts the terminal cutting speed and the initial cutting speed of the cutting routes. The speed determination engine performs speed planning on the cutting routes according to digital control system period time. A cutting speed planning method and a non-transitory storage medium are further provided.

Abstract: This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

Abstract: A compound of a first ligand LA of Formula I, is provided. In Formula I, moieties A and B are each a monocyclic ring or a polycyclic fused-ring system; Z1 to Z4 are each C or N; K is a direct bond, O, or S; each RA and RB is independently a hydrogen or a General Substituent; at least one RA or RB is R*, wherein R* has a structure of Formula II, ---L-GeR1R2R3; L is a direct bond or an organic linker; and LA is coordinated to a metal M by the dashed lines; and metal M is selected from Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, or Cu.

Abstract: Provided are organometallic compounds based on platin or palladium and their various uses including as emitters in devices having the structure of Formula I comprising at least four rings as defined herein. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices and related consumer products that utilize these compounds.

Abstract: A compound including a tetradentate ligand, LA, is provided. In the compound, LA is coordinated to a metal M selected from Pt, Pd, Cu, Ag, and Au; LA comprises a first moiety and a second moiety that are different form each other and are independently coordinated to the metal M; the first moiety is a heterocyclic carbene, that is coordinated to the metal M through a metal-carbene bond, while the second moiety is a 5-membered heterocycle; and the ligand LA forms at least one M-O or M-S bond. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound having a formula of M(LA)p(LB)q(LC)r, where LA has a structure of Formula I, LB is a bidentate ligand; and LC has a structure of Formula II, is provided. In Formula I and Formula II, the compound can be homoleptic or heteroleptic and can include up to three different ligands; K3 and K4 are each independently a direct bond, O, or S; each of moiety A and moiety B represents a monocyclic ring or a polycyclic, fused-ring structure; each of Z1 and Z2 is C or N; and at least one of RA, RB, RC1, RC2, or RC3 comprises a structure of Formula III, In Formula III, L is bivalent organic linker, and Z is Si or Ge. Each RA, RB, RC1, RC2, and RC3 is independently hydrogen or a General Substituent, and each of R1, R2, and R3 is a General Substituent. Formulations, OLEDs, and consumer products including such compounds are also provided.

Abstract: A compound of Formula I, is provided. In Formula I, rings A, B, and D are independently 5- or 6-membered rings; Z1-Z3 and X1-X5 are independently C or N; each of K1 and K2 are a direct bond, O, and S; Y1 is BR, NR1, O, S, Se, or CRR?; represents a single bond or no bond; when present, L1, L2, L3, and L4 are each independently a direct bond or a linker; each substituent is hydrogen or a general substituent and can be joined together to form a ring. Formulations, OLEDs, and consumer products containing the same are also provided.

Abstract: Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: Provided is a compound comprising a first ligand LA of